Ardelyx (ARDX)

The company’s lead compound is tenapanor, which Ardelyx markets under two different brand names for separate indications. IBSRELA is approved for adults with irritable bowel syndrome with constipation, commonly known as IBS-C. It works by inhibiting the sodium/hydrogen exchanger NHE3 in the intestinal tract, which helps increase bowel movements and reduce constipation-related symptoms.

Tenapanor is also sold as XPHOZAH for adults with chronic kidney disease on dialysis who need additional control of serum phosphorus. In that setting, XPHOZAH is used as add-on therapy for patients who do not respond adequately to phosphate binders or who cannot tolerate phosphate binder therapy. Its mechanism reduces phosphate absorption in the intestines, offering a different approach from traditional phosphate-binding products.

Ardelyx combines commercial operations with ongoing clinical and regulatory work. Its revenue potential depends on physician adoption, payer access, dialysis-market penetration, and the company’s ability to differentiate tenapanor from established therapies. As a listed biotech stock, ARDX is closely tied to prescription growth, safety data, reimbursement decisions, and the broader market’s view of specialty pharmaceutical companies addressing gastrointestinal and renal disease.